Smith & Nephew

SNN · LONDON

$30.83−$0.05 (−0.16%)TodayMarket closed · Oct 23, 7:30 PM ET

Prev close $30.88

SNN analyst rating

HoldConsensus of 4 analysts over the last 12 months. 0% rate it a buy.

Strong buy0
Buy0
Hold3
Underperform1
Sell0

12-month price target · 19 analysts

Average $33.77 (+9.6% upside)

Low: $28.48
Now: $30.83
High: $43.70

Upgrades and downgrades

The latest rating actions, newest first

SNN analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
BTIG	Aug 31, 2026	Initiates	Neutral	—	48%
JP Morgan	Aug 6, 2026	Downgrade	Overweight → Neutral	—	67%
Barclays	Aug 5, 2026	Downgrade	Equal-Weight → Underweight	—	100%
Canaccord Genuity	May 11, 2026	Maintains	Hold	$32.00 → $30.00	43%
Canaccord Genuity	Mar 5, 2026	Maintains	Hold	$34.00 → $35.00	43%
Canaccord Genuity	Nov 11, 2025	Maintains	Hold	$36.00 → $34.00	43%

The case for and against

Updated Aug 14, 2025

Bull case

Smith & Nephew is experiencing underlying growth in key segments, with a notable increase of 5.5% in orthopedic products, driven by positive traction in the US market. The company has demonstrated strong performance in enabling technologies, particularly with a 23.9% underlying growth in Other Reconstruction, attributed to a significant rise in CORI placements. Furthermore, Smith & Nephew expects improved trading margins, anticipating a stronger performance in the second half of the year, supported by operational enhancements and a projected growth rate of 5% for 2025.

Bear case

Smith & Nephew's forecast for FY25 indicates potential revenue challenges, particularly in Q1, due to factors such as fewer selling days and ongoing inventory issues in China, which could hinder performance. The company's return on invested capital (ROIC) in the orthopedic segment remains significantly lower than that of its sports medicine and advanced wound management divisions, reflecting inefficiencies that may not be resolved in the near term. Additionally, the evolving US healthcare landscape poses risks from decreasing reimbursement rates, alongside persistent headwinds in the Chinese market related to political and regulatory uncertainties.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.